D-37/1,TTC MIDC,Turbhe, Navi Mumbai-400 703









Corporate Office: Thyrocare Technologies Limited ♥ D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703 © 022 - 3090 0000 / 4125 2525 ● 8691866066 ■ wellness@thyrocare.com ● www.thyrocare.com



REPORT

**SAMPLE COLLECTED AT:** 

ANANYA MAHARANA BRAHMIN PARA BALANGIR

BALANGIR ODISHA 767001,767001

**REF. BY** : DSA OWN - AAROGYAM 1.2

**TEST ASKED**: AAROGYAM 1.2

TEST NAME
TECHNOLOGY
VALUE
UNITS

HbA1c - (HPLC - NGSP Certified)
H.P.L.C
5 %

Reference Range:

Reference Range: As per ADA Guidelines

Below 5.7% : Normal 5.7% - 6.4% : Prediabetic >=6.5% : Diabetic

Guidance For Known Diabetics

Below 6.5% : Good Control 6.5% - 7% : Fair Control

7.0% - 8% : Unsatisfactory Control

>8% : Poor Control

Method: Fully Automated H.P.L.C. using Biorad Variant II Turbo, NGSP Certified.

AVERAGE BLOOD GLUCOSE (ABG) CALCULATED 97 mg/dl

Reference Range:

90 - 120 mg/dl : Good Control 121 - 150 mg/dl : Fair Control

151 - 180 mg/dl: Unsatisfactory Control

> 180 mg/dl : Poor Control

Method: Derived from HBA1c values

Please correlate with clinical conditions.

Sample Collected on (SCT)
Sample Received on (SRT)
Report Released on (RRT)

Sample Type

Labcode Barcode :14 Oct 2019 08:30 :16 Oct 2019 02:08

:16 Oct 2019 04:42

: EDTA

:1510050103/ORI07

:00053946

1000

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Sengupta MD(Micro)

Page : 1 of 12

REF. BY

**TEST ASKED** 

D-37/1,TTC MIDC,Turbhe, Navi Mumbai-400 703

: DSA OWN - AAROGYAM 1.2

: AAROGYAM 1.2







Corporate Office: Thyrocare Technologies Limited P D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703 



SAMPLE COLLECTED AT :

ANANYA MAHARANA BRAHMIN PARA BALANGIR

BALANGIR ODISHA 767001,767001

TEST NAME	VALUE	UNITS	REFERENCE RANGE
TOTAL LEUCOCYTES COUNT	6.71	X 10 <sup>3</sup> / μL	4.0-10.0
NEUTROPHILS	74.7	%	40-80
LYMPHOCYTE PERCENTAGE	19.4	%	20-40
MONOCYTES	1.5	%	0-10
EOSINOPHILS	3.9	%	0.0-6.0
BASOPHILS	0.2	%	<2
IMMATURE GRANULOCYTE PERCENTAGE(IG%)	0.3	%	0-0.5
NEUTROPHILS - ABSOLUTE COUNT	5.01	$X~10^3$ / $\mu L$	2.0-7.0
LYMPHOCYTES - ABSOLUTE COUNT	1.3	$X 10^{3} / \mu L$	1.0-3.0
MONOCYTES - ABSOLUTE COUNT	0.1	X 10 <sup>3</sup> / μL	0.2-1
BASOPHILS - ABSOLUTE COUNT	0.01	$X 10^{3} / \mu L$	0-0.1
EOSINOPHILS - ABSOLUTE COUNT	0.26	$X~10^3$ / $\mu L$	0-0.5
IMMATURE GRANULOCYTES(IG)	0.02	$X 10^{3} / \mu L$	0-0.3
TOTAL RBC	5.94	X 10^6/μL	4.5-5.5
NUCLEATED RED BLOOD CELLS	Nil	$X~10^3$ / $\mu L$	<0.01
NUCLEATED RED BLOOD CELLS %	Nil	%	<0.01
HEMOGLOBIN	12.1	g/dL	13-17
HEMATOCRIT(PCV)	45.6	%	40-50
MEAN CORPUSCULAR VOLUME(MCV)	76.8	fL	83-101
MEAN CORPUSCULAR HEMOGLOBIN(MCH)	20.4	pq	27-32
MEAN CORP.HEMO.CONC(MCHC)	26.5	g/dL	31.5-34.5
RED CELL DISTRIBUTION WIDTH - SD(RDW-SD)	45.5	fL	39-46
RED CELL DISTRIBUTION WIDTH (RDW-CV)	18.3	%	11.6-14
PLATELET DISTRIBUTION WIDTH(PDW)	16.67	fL	9.6-15.2
MEAN PLATELET VOLUME(MPV)	11.5	fL	6.5-12
PLATELET COUNT	179	$X~10^3$ / $\mu L$	150-400
PLATELET TO LARGE CELL RATIO(PLCR)	36	%	19.7-42.4
PLATELETCRIT(PCT)	0.17	%	0.19-0.39

ALERT !!! Hypochromia, Anisocytosis Remarks:

Please Correlate with clinical conditions.

Method: Fully automated bidirectional analyser (6 Part Differential SYSMEX XN-1000)

(This device performs hematology analyses according to the Hydrodynamic Focussing (DC method), Flow

Cytometry Method (using a semiconductor laser), and SLS- hemoglobin method)

Sample Collected on (SCT) :14 Oct 2019 08:30 Sample Received on (SRT) :16 Oct 2019 02:08 Report Released on (RRT) :16 Oct 2019 04:42

**Sample Type** : EDTA

**Barcode** 

Labcode : 1510050103/ORI07

: 00053946

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Sengupta MD(Micro)

Page: 2 of 12

D-37/1,TTC MIDC,Turbhe, Navi Mumbai-400 703







Corporate Office: Thyrocare Technologies Limited D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703 

REPORT

**SAMPLE COLLECTED AT:** 

ANANYA MAHARANA BRAHMIN PARA BALANGIR

BALANGIR ODISHA 767001,767001

**TECHNOLOGY VALUE UNITS TEST NAME IMMUNOTURBIDIMETRY** LIPOPROTEIN (A) [LP(A)] 33.6 mg/dl Reference Range :-

ADULTS: < 30.0 MG/DL

INTERPRETATION:

**REF. BY** 

**TEST ASKED** 

DETERMINATION OF LPA MAY BE USEFUL TO GUIDE MANAGEMENT OF INDIVIDUALS WITH A FAMILY HISTORY OF CHD OR WITH EXISTING DISEASE. THE LEVELS OF LPA IN THE BLOOD DEPENDS ON GENETIC FACTORS; THE RANGE OF VARIATION IN A POPULATION IS RELATIVELY LARGE AND HENCE FOR DIAGNOSTIC PURPOSE, RESULTS SHOULD ALWAYS BE ASSESSED IN CONJUNCTION WITH THE PATIENT'S MEDICAL HISTORY, CLINICAL EXAMINATION AND OTHER FINDINGS.

SPECIFICATIONS:

PRECISION: INTRA ASSAY (%CV): 3.4 %, INTER ASSAY (%CV): 2.0 %; SENSITIVITY: 0.002 GM/L

EXTERNAL QUALITY CONTROL PROGRAM PARTICIPATION:

: DSA OWN - AAROGYAM 1.2

: AAROGYAM 1.2

COLLEGE OF AMERICAN PATHOLOGISTS: GENERAL CHEMISTRY AND TDM; CAP NUMBER: 7193855-01

KIT VALIDATION REFERENCES:

KOSCHINSKY ML, MARCOVINA SM. LIPOPROTEIN A: STRUCTURAL IMPLICATION FOR PATHOPHYSIOLOGY. INT J CLIN LAB RES, 1997; 27: 14-23.

Please correlate with clinical conditions.

Method:- LATEX ENHANCED IMMUNOTURBIDIMETRY

Sample Collected on (SCT) :14 Oct 2019 08:30 Sample Received on (SRT) :16 Oct 2019 02:22 Report Released on (RRT) :16 Oct 2019 07:10

**Sample Type** : SERUM

Labcode : 1510051461/ORI07

**Barcode** : N9368222

Dr.Prachi Sinkar MD(Path)

Dr. Caesar Sengupta MD(Micro)

Page: 3 of 12

REF. BY

**TEST ASKED** 

D-37/1,TTC MIDC,Turbhe, Navi Mumbai-400 703









: DSA OWN - AAROGYAM 1.2

: AAROGYAM 1.2

Corporate Office: Thyrocare Technologies Limited ♥ D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703

**REPORT** 

**SAMPLE COLLECTED AT:** 

ANANYA MAHARANA BRAHMIN PARA BALANGIR

BALANGIR ODISHA 767001,767001

**TEST NAME TECHNOLOGY VALUE** UNITS **APOLIPOPROTEIN - A1 (APO-A1) IMMUNOTURBIDIMETRY** 112 mg/dL Reference Range: MALE : 86 - 152 FEMALE : 94 - 162 Method: FULLY AUTOMATED RATE IMMUNOTURBIDIMETRY - BECKMAN COULTER **IMMUNOTURBIDIMETRY** 101 **APOLIPOPROTEIN - B (APO-B)** mg/dL Reference Range: MALE : 56 - 145 FEMALE : 53 - 138 Method: FULLY AUTOMATED RATE IMMUNOTURBIDIMETRY - BECKMAN COULTER **CALCULATED** 0.9 Ratio APO B / APO A1 RATIO (APO B/A1) Reference Range:

MALE : 0.40 - 1.26 FEMALE : 0.38 - 1.14

Method: DERIVED FROM SERUM APO A1 AND APO B VALUES

Please correlate with clinical conditions.

 Sample Collected on (SCT)
 :14 Oct 2019 08:30

 Sample Received on (SRT)
 : 16 Oct 2019 02:22

 Report Released on (RRT)
 : 16 Oct 2019 07:10

Sample Type : SERUM

**Labcode** : 1510051461/ORI07

Barcode : N9368222

Macagan

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Sengupta MD(Micro)

Page: 4 of 12

D-37/1,TTC MIDC,Turbhe, Navi Mumbai-400 703







Think Thyroid. Think Thyrocare.

Corporate Office: Thyrocare Technologies Limited D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703

: AAROGYAM 1.2

: DSA OWN - AAROGYAM 1.2

REPORT

**SAMPLE COLLECTED AT:** 

ANANYA MAHARANA BRAHMIN PARA BALANGIR

BALANGIR ODISHA 767001,767001

**TECHNOLOGY VALUE UNITS TEST NAME IMMUNOTURBIDIMETRY** HIGH SENSITIVITY C-REACTIVE PROTEIN (HS-CRP) 0.5 mg/L

Reference Range :-

ADULT: <=3.0 MG/L

#### INTERPRETATION:

REF. BY

**TEST ASKED** 

HIGH SENSITIVITY C-REACTIVE PROTEIN, WHEN USED IN CONJUNCTION WITH OTHER CLINICAL LABORATORY EVALUATION OF ACUTE CORONARY SYNDROMES, MAY BE USEFUL AS AN INDEPENDENT MARKER OF PROGNOSIS FOR RECURRENT EVENTS, IN PATIENTS WITH STABLE CORONARY DISEASE OR ACUTE CORONARY SYNDROMES. HSCRP LEVELS SHOULD NOT BE SUBSTITUTED FOR ASSESSMENT OF TRADITIONAL CARDIOVASCULAR RISK FACTORS. PATIENTS WITH PERSISTENTLY UNEXPLAINED, MARKED EVALUATION OF HSCRP AFTER REPEATED TESTING SHOULD BE EVALUATED FOR NON - CARDIOVASCULAR ETIOLOGIES

#### CLINICAL SIGNIFICANCE:

HSCRP MEASUREMENTS MAY BE USED AS AN INDEPENDENT RISK MARKER FOR THE IDENTIFICATION OF INDIVIDUALS AT RISK FOR FUTURE CARDIOVASCULAR DISEASE. ELEVATED CRP VALUES MAY BE INDICATIVE OF PROGNOSIS OF INDIVIDUALS WITH ACUTE CORONARY SYNDROMES, AND MAY BE USEFUL IN THE MANAGEMENT OF SUCH INDIVIDUALS.

SPECIFICATIONS: PRECISION: WITHIN RUN %CV HAS BEEN RECORDED <=5%.

#### **REFERENCES:**

- 1. CHENILLOT O, HENNY J, STEINMEZ J, ET AL. HIGH SENSITIVITY C-REACTIVE PROTEIN: BIOLOGICAL VARIATIONS AND REFERENCE LIMITS. CLIN CHEM LAB MED 2000;38:1003-11.
- 2. HIND CRH, PEPYS MB. THE ROLE OF SERUM C-REACTIVE PROTEIN MEASUREMENTS IN CLINICAL PRACTICE. INT MED 1984;5:112-51.

### Please correlate with clinical conditions.

Method:- FULLY AUTOMATED LATEX AGGLUTINATION - BECKMAN COULTER

Sample Collected on (SCT) :14 Oct 2019 08:30 Sample Received on (SRT) :16 Oct 2019 02:22 Report Released on (RRT) :16 Oct 2019 07:10

**Sample Type** : SERUM

Labcode : 1510051461/ORI07

: N9368222 **Barcode** 

Dr.Prachi Sinkar MD(Path)

Dr. Caesar Sengupta MD(Micro)

Page: 5 of 12

D-37/1,TTC MIDC,Turbhe, Navi Mumbai-400 703









**REF. BY** 

**TEST ASKED** 

Corporate Office: Thyrocare Technologies Limited ♥ D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703

REPORT

**SAMPLE COLLECTED AT:** 

ANANYA MAHARANA BRAHMIN PARA BALANGIR

BALANGIR ODISHA 767001,767001

TEST NAME	TECHNOLOGY	VALUE	UNITS
IRON	PHOTOMETRY	101.4	μg/dl
Reference Range: Male: 65 - 175			
Female: 50 - 170			
Method: FERROZINE METHOD WITHOUT DEPROTEINIZA	ATION		
TOTAL IRON BINDING CAPACITY (TIBC)	PHOTOMETRY	343	μg/dl
Reference Range : Male: 225 - 535 μg/dl Female: 215 - 535 μg/dl Method : SPECTROPHOTOMETRIC ASSAY			
% TRANSFERRIN SATURATION	CALCULATED	29.56	%
Reference Range:			

DERIVED FROM IRON AND TIBC VALUES Please correlate with clinical conditions.

: DSA OWN - AAROGYAM 1.2

: AAROGYAM 1.2

:14 Oct 2019 08:30 Sample Collected on (SCT) Sample Received on (SRT) :16 Oct 2019 02:22 Report Released on (RRT) :16 Oct 2019 07:10

: SERUM **Sample Type** 

Labcode : 1510051461/ORI07

**Barcode** : N9368222

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Sengupta MD(Micro)

Page: 6 of 12

REF. BY

**TEST ASKED** 

D-37/1,TTC MIDC,Turbhe, Navi Mumbai-400 703







Think Thyroid. Think Thyrocare.

Corporate Office: Thyrocare Technologies Limited P D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703

: DSA OWN - AAROGYAM 1.2

: AAROGYAM 1.2

REPORT

**SAMPLE COLLECTED AT:** 

ANANYA MAHARANA BRAHMIN PARA BALANGIR

BALANGIR ODISHA 767001,767001

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
ALKALINE PHOSPHATASE	PHOTOMETRY	91.1	U/L	45 - 129
BILIRUBIN -DIRECT	PHOTOMETRY	0.33	mg/dl	< 0.3
BILIRUBIN - TOTAL	PHOTOMETRY	2.23	mg/dl	0.3-1.2
BILIRUBIN (INDIRECT)	CALCULATED	1.9	mg/dl	0-0.9
GAMMA GLUTAMYL TRANSFERASE (GGT)	PHOTOMETRY	46.5	U/I	< 55
ASPARTATE AMINOTRANSFERASE (SGOT )	PHOTOMETRY	28.3	U/I	< 35
ALANINE TRANSAMINASE (SGPT)	PHOTOMETRY	38.3	U/I	< 45
PROTEIN - TOTAL	PHOTOMETRY	7.47	gm/dl	5.7-8.2
ALBUMIN - SERUM	PHOTOMETRY	4.67	gm/dl	3.2-4.8
SERUM GLOBULIN	PHOTOMETRY	2.8	gm/dL	2.5-3.4
SERUM ALB/GLOBULIN RATIO	CALCULATED	1.67	Ratio	0.9 - 2

#### Please correlate with clinical conditions.

#### Method:

ALKP - Modified IFCC method

BILD - Vanadate Oxidation

BILT - Vanadate Oxidation

BILI - DERIVED FROM SERUM TOTAL AND DIRECT BILIRUBIN VALUES

GGT - Modified IFCC method

SGOT - IFCC\* WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION

SGPT - IFCC\* WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION

PROT - BIURET METHOD

SALB - ALBUMIN BCG<sup>1</sup>METHOD (COLORIMETRIC ASSAY ENDPOINT)

SEGB - DERIVED FROM SERUM ALBUMIN AND PROTEIN VALUES

A/GR - DERIVED FROM SERUM ALBUMIN AND PROTEIN VALUES

Sample Collected on (SCT) : 14 Oct 2019 08:30 Sample Received on (SRT) : 16 Oct 2019 02:22

Report Released on (RRT) : 16 Oct 2019 07:10

: SERUM **Sample Type** 

Labcode : 1510051461/ORI07

: N9368222 **Barcode** 

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Sengupta MD(Micro)

Page: 7 of 12

REF. BY

**TEST ASKED** 

D-37/1,TTC MIDC,Turbhe, Navi Mumbai-400 703







Think Thyroid. Think Thyrocare.

< 160

Corporate Office: Thyrocare Technologies Limited D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703

REPORT

**SAMPLE COLLECTED AT:** 

119.6

ANANYA MAHARANA BRAHMIN PARA BALANGIR

mg/dl

BALANGIR ODISHA 767001,767001

TEST NAME	TECHNOLOGY	VALUE	UNITS	<b>NORMAL RANGE</b>
TOTAL CHOLESTEROL	PHOTOMETRY	153	mg/dl	125-200
HDL CHOLESTEROL - DIRECT	PHOTOMETRY	34	mg/dl	35-80
LDL CHOLESTEROL - DIRECT	PHOTOMETRY	90	mg/dl	85-130
TRIGLYCERIDES	PHOTOMETRY	238	mg/dl	25-200
TC/ HDL CHOLESTEROL RATIO	CALCULATED	4.5	Ratio	3 - 5
LDL / HDL RATIO	CALCULATED	2.7	Ratio	1.5-3.5
VLDL CHOLESTEROL	CALCULATED	47.58	mg/dl	5 - 40

**CALCULATED** 

#### Please correlate with clinical conditions.

#### Method:

CHOL - CHOD POD METHOD

NON-HDL CHOLESTEROL

HCHO - ENZYME SELECTIVE PROTECTION METHOD

LDL - HOMOGENOUS ENZYMATIC COLORIMETRIC ASSAY

: DSA OWN - AAROGYAM 1.2

: AAROGYAM 1.2

TRIG - ENZYMATIC COLORIMETRIC METHOD (GPO) [HIGHLY INFLUENCED BY LEVEL OF FASTING]

TC/H - DERIVED FROM SERUM CHOLESTEROL AND HDL VALUES

LDL/ - Derived from serum HDL and LDL Values

VLDL - DERIVED FROM SERUM TRIGLYCERIDE VALUES

NHDL - Derived from serum Cholesterol and HDL values

#### \*REFERENCE RANGES AS PER NCEP ATP III GUIDELINES:

TOTAL CHOLESTEROL	(mg/dl)	HDL	(mg/dl)	LDL	(mg/dl)	TRIGLYCERIDES	(mg/dl)
DESIRABLE	<200	LOW	<40	OPTIMAL	<100	NORMAL	<150
BORDERLINE HIGH	200-239	HIGH	>60	NEAR OPTIMAL	100-129	BORDERLINE HIGH	150-199
HIGH	>240			BORDERLINE HIGH	130-159	HIGH	200-499
				HIGH	160-189	VERY HIGH	>500
				VERY HIGH	>190		

Alert !!! 10-12 hours fasting is mandatory for lipid parameters. If not, values might fluctuate.

: 16 Oct 2019 02:22

Sample Collected on (SCT) : 14 Oct 2019 08:30

Report Released on (RRT) : 16 Oct 2019 07:10

: SERUM **Sample Type** 

Sample Received on (SRT)

Labcode : 1510051461/ORI07

**Barcode** : N9368222 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Sengupta MD(Micro)

Page: 8 of 12

#### **PROCESSED AT:**

#### **Thyrocare**

**REF. BY** 

D-37/1,TTC MIDC,Turbhe, Navi Mumbai-400 703









Corporate Office: Thyrocare Technologies Limited ♥ D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703 

### REPORT

SAMPLE COLLECTED AT :

ANANYA MAHARANA BRAHMIN PARA BALANGIR

BALANGIR ODISHA 767001,767001

**TEST ASKED** : AAROGYAM 1.2

TEST NAME	TECHNOLOGY	VALUE	UNITS REFERENCE RANGE
TOTAL TRIIODOTHYRONINE (T3)	C.L.I.A	101	ng/dl 60-200
TOTAL THYROXINE (T4)	C.L.I.A	6.9	μg/dl 4.5-12
THYROID STIMULATING HORMONE (TSH)	C.L.I.A	1.03	μIU/ml 0.3-5.5

Comments: SUGGESTING THYRONORMALCY

Please correlate with clinical conditions.

Method:

T3 - COMPETITIVE CHEMI LUMINESCENT IMMUNO ASSAY

: DSA OWN - AAROGYAM 1.2

T4 - COMPETITIVE CHEMI LUMINESCENT IMMUNO ASSAY

TSH - SANDWICH CHEMI LUMINESCENT IMMUNO ASSAY

Sample Collected on (SCT) : 14 Oct 2019 08:30 Sample Received on (SRT) : 16 Oct 2019 02:22 Report Released on (RRT) : 16 Oct 2019 07:10

**Sample Type** : SERUM

Labcode : 1510051461/ORI07

**Barcode** : N9368222

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Sengupta MD(Micro)

Page: 9 of 12

D-37/1,TTC MIDC,Turbhe, Navi Mumbai-400 703







Think Thyroid. Think Thyrocare.

Corporate Office: Thyrocare Technologies Limited P D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703

: DSA OWN - AAROGYAM 1.2

**SAMPLE COLLECTED AT:** 

ANANYA MAHARANA BRAHMIN PARA BALANGIR

BALANGIR ODISHA 767001,767001

**REPORT** 

**TEST ASKED** : AAROGYAM 1.2

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
BLOOD UREA NITROGEN (BUN)	PHOTOMETRY	6.16	mg/dl	7 - 25
CREATININE - SERUM	PHOTOMETRY	0.64	mg/dl	0.6-1.1
URIC ACID	PHOTOMETRY	6.28	mg/dl	4.2 - 7.3
CALCIUM	PHOTOMETRY	9.94	mg/dl	8.8-10.6
BUN / SR.CREATININE RATIO	CALCULATED	9.63	Ratio	9:1-23:1

#### Please correlate with clinical conditions.

#### Method:

REF. BY

BUN - KINETIC UV ASSAY.

SCRE - CREATININE ENZYMATIC METHOD

URIC - Uricase / Peroxidase Method

CALC - ARSENAZO III METHOD, END POINT.

B/CR - DERIVED FROM SERUM BUN AND CREATININE VALUES

Sample Collected on (SCT)

: 14 Oct 2019 08:30

Sample Received on (SRT) Report Released on (RRT) : 16 Oct 2019 02:22 : 16 Oct 2019 07:10

Sample Type

: SERUM

Labcode

: 1510051461/ORI07

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Sengupta MD(Micro)

**Barcode** : N9368222

Page: 10 of 12

REF. BY

**TEST ASKED** 

D-37/1,TTC MIDC,Turbhe, Navi Mumbai-400 703



Think Thyroid. Think Thyrocare.

mL/min/1.73 m2

Corpor

Corporate Office: Thyrocare Technologies Limited ♥ D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703 © 022 - 3090 0000 / 4125 2525 ♥ 8691866066 ➤ wellness@thyrocare.com ® www.thyrocare.com

**REPORT** 

**CALCULATED** 

SAMPLE COLLECTED AT :

ANANYA MAHARANA BRAHMIN PARA BALANGIR BALANGIR ODISHA 767001,767001

109

TEST NAME

TECHNOLOGY VALUE UNITS

EST. GLOMERULAR FILTRATION RATE (eGFR)

: AAROGYAM 1.2

: DSA OWN - AAROGYAM 1.2

Reference Range :-

> = 90 : Normal 60 - 89 : Mild Decrease

45 - 59 : Mild to Moderate Decrease 30 - 44 : Moderate to Severe Decrease

15 - 29 : Severe Decrease

#### Clinical Significance

The normal serum creatinine reference interval does not necessarily reflect a normal GFR for a patient. Because mild and moderate kidney injury is poorly inferred from serum creatinine alone. Thus, it is recommended for clinical laboratories to routinely estimate glomerular filtration rate (eGFR), a "gold standard" measurement for assessment of renal function, and report the value when serum creatinine is measured for patients 18 and older, when appropriate and feasible. It cannot be measured easily in clinical practice, instead, GFR is estimated from equations using serum creatinine, age, race and sex. This provides easy to interpret information for the doctor and patient on the degree of renal impairment since it approximately equates to the percentage of kidney function remaining. Application of CKD-EPI equation together with the other diagnostic tools in renal medicine will further improve the detection and management of patients with CKD.

#### Reference

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.

Please correlate with clinical conditions.

Method:- CKD-EPI Creatinine Equation

~~ End of report ~~

Sample Collected on (SCT)

Sample Received on (SRT)

Report Released on (RRT)

Sample Type

Labcode

Barcode

: 14 Oct 2019 08:30

:16 Oct 2019 02:22

:16 Oct 2019 07:10

: SERUM

:1510051461/ORI07

: N9368222

Dr.Prachi Sinkar MD(Path)

ath)

Dr.Caesar Sengupta MD(Micro)

Page: 11 of 12

#### CONDITIONS OF REPORTING

- The reported results are for information and interpretation of the referring doctor only.
- It is presumed that the tests performed on the specimen belong to the patient; named or identified.
- Results of tests may vary from laboratory to laboratory and also in some parameters from time to time for the same patient.
- Should the results indicate an unexpected abnormality, the same should be reconfirmed.
- Only such medical professionals who understand reporting units, reference ranges and limitations of technologies should interpret results.
- This report is not valid for medico-legal purpose.
- Neither Thyrocare, nor its employees/representatives assume any liability, responsibility for any loss or damage that may be incurred by any person as a result of presuming the meaning or contents of the report.

#### **EXPLANATIONS**

- Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them as "Clients".
- Name The name is as declared by the client and recored by the personnel who collected the specimen.
- \* Ref.Dr The name of the doctor who has recommended testing as declared by the client.
- ❖ Labcode This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
- Barcode This is the specimen identity number and it states that the results are for the specimen bearing the barcode (irrespective of the name).
- SCP Specimen Collection Point This is the location where the blood or specimen was collected as declared by the client.
- SCT Specimen Collection Time The time when specimen was collected as declared by the client.
- SRT Specimen Receiving Time This time when the specimen reached our laboratory.
- \* RRT Report Releasing Time The time when our pathologist has released the values for Reporting.
- Reference Range Means the range of values in which 95% of the normal population would fall.

#### **SUGGESTIONS**

- Values out of reference range requires reconfirmation before starting any medical treatment.
- Retesting is needed if you suspect any quality shortcomings.
- Testing or retesting should be done in accredited laboratories.
- For suggestions, complaints or feedback, write to us at info@thyrocare.com or call us on 022-3090 0000 / 4125 2525
- SMS:<Labcode No.> to 9870666333

















# "Fight TB with power of Rapid Technology"

Focus TB, powered by Thyrocare.

A brand that will focus on TB, which is one of the major public health problems in the country.

Tuberculosis (TB) is a transmissible, airborne infection caused by Mycobacterium tuberculosis (MTB). It transpires usually when a person inhales microscopic droplet nuclei containing viable bacteria, spread through coughing by persons who have infectious TB.

Call: 022 - 3090 0000/4125 2525 Email: info@focustb.com Website: www.focustb.com



Page: 12 of 12